

EFFECTIVE FOR DATES OF SERVICE BEGINNING OCTOBER 1, 2022

VABYSMO[®] (faricimab-svoa) Permanent J-code Is Available



The Centers for Medicare & Medicaid Services has assigned a permanent J-code for VABYSMO effective October 1, 2022.


VABYSMO received FDA approval on January 28, 2022, for the treatment of patients with Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).

J2777: Injection, faricimab-svoa, 0.1 mg

- ✓ J2777 becomes effective October 1, 2022
- ✓ J2777 may assist you as you complete the payer forms for VABYSMO
- ✓ Bill 60 units for the 6-mg administered dose of VABYSMO
- ✓ J2777 is recognized by government and commercial payers

Contact your Field Reimbursement Manager for more information on the permanent J-code for VABYSMO or for access and reimbursement support. You can choose how to connect with us:

 Visit [VABYSMO.com/support](https://www.vabysmo.com/support)

 Call **(833) EYE-GENE**/(833) 393-4363,
Monday–Friday, 9 a.m.–8 p.m. ET

FDA=US Food and Drug Administration.

Genentech
A Member of the Roche Group

VABYSMO is a registered trademark of Genentech, Inc., and the VABYSMO logo is a trademark of Genentech, Inc.

©2022 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00017058(v1.0) 08/22 Printed in USA